Context.—

High-resolution computed tomography (HRCT) imaging has an increasingly important role in clinical decision-making in patients with interstitial lung diseases. The recent Fleischner Society white paper on the diagnostic criteria for idiopathic pulmonary fibrosis highlights the advances in our understanding of HRCT imaging in interstitial lung diseases.

Objective.—

To discuss the evidence and recommendations outlined in the white paper as it pertains to the radiologic diagnosis of interstitial lung disease, specifically highlighting the current limitations of HRCT in confidently predicting histopathologic findings.

Data Sources.—

The recent Fleischner Society white paper and other studies pertaining to the role of HRCT in predicting histopathology in interstitial lung diseases are reviewed.

Conclusions.—

High-resolution computed tomography is highly predictive of a usual interstitial pneumonia (UIP) pattern on histopathology when the HRCT shows a typical UIP pattern on a “confident” read by the radiologist. A probable UIP pattern is also very predictive of a UIP pattern on histopathology, and histopathologic confirmation is not needed for most patients demonstrating this pattern in the appropriate clinical setting. A UIP pattern may be seen in a substantial proportion of patients with an “indeterminate UIP” pattern on HRCT and in many patients for whom the HRCT suggests an alternative diagnosis; histopathologic confirmation should be considered in patients demonstrating these patterns whenever feasible.

As our understanding of the natural histories of various interstitial lung diseases (ILDs) has evolved, so has the recognition that certain radiologic patterns are correlated with specific histopathologic patterns in patients with ILDs.1  High-resolution computed tomography (HRCT) imaging is having an increasingly more important role in clinical decision-making in patients with ILDs, but, as with any other diagnostic tool, it is important to understand its performance characteristics and to recognize its limitations.

The 2011 official American Thoracic Society and European Respiratory Society (ATS/ERS) statement on the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), among other recommendations, recognized that a histopathologic confirmation was not needed in patients with idiopathic ILD who had a usual interstitial pneumonia (UIP) pattern on HRCT of the chest.2  This recommendation was based on high-quality studies correlating HRCT findings with histopathology. Those studies showed that a “confident” HRCT read, demonstrating a “definite” UIP pattern, were 95% to 100% specific in predicting a UIP pattern on histopathology.37  The 2011 IPF statement2  was very specific in stating that the need for histopathologic confirmation can be obviated only in idiopathic ILD demonstrating a UIP pattern and recommended a biopsy in patients with an ILD demonstrating other patterns.

Anecdotally, it has been our experience that there has been a tendency in the past few years in some academic and nonacademic centers treating patients with ILDs toward extrapolating the findings in a “confident read of a definite UIP pattern on HRCT chest” to other HRCT patterns, perhaps, without supporting evidence. This has translated clinically in a tendency to avoid histopathologic confirmation in many patients who have patterns other than UIP on HRCT, despite those patients being otherwise good surgical candidates. Varying proportions of those patients with idiopathic ILDs who demonstrate patterns other than a UIP pattern are labeled with an ILD diagnosis based on radiology alone. An unknown number of those patients would likely have had an alternative diagnosis had histopathology been pursued as part of the workup.

The recent timely and very comprehensive Fleischner Society white paper1  on the diagnostic criteria of IPF highlights recent advances in our understanding of HRCT imaging in ILDs, and perhaps, importantly, the pitfalls and current gaps in our understanding of the utility of HRCT imaging in predicting histopathology in patients with ILDs. In this article, we discuss the evidence and recommendations outlined in the white paper as they pertain to the radiologic diagnosis of ILD.

The Fleischner society paper notes that, in line with the previous guidelines,2  the histopathologic confirmation is not needed in the context of a “typical UIP pattern,” which demonstrates basal-predominant (occasionally diffuse) and subpleural-predominant, often heterogeneous, reticular opacities with peripheral traction bronchiectasis or bronchiolectasis, with honeycombing, and an absence of features to suggest an alternative diagnosis1  (Table). Corresponding histopathologic findings in UIP include temporally and spatially heterogenous fibrosis, which is predominantly subpleural, with fibroblastic foci and honeycombing.1  UIP histopathologic pattern can be seen in various clinical contexts such as hypersensitivity pneumonitis, and connective tissue diseases. If a UIP pattern is noted on HRCT and/or histopathology, a diagnosis of IPF is made when no “secondary” causes for the ILD can be identified after a reasonably diligent history, physical examination, and laboratory investigation.

Comparison of the 2011 American Thoracic Society and European Respiratory Society (ATS/ERS) Guidelines2  and the 2018 Fleischner Society White Paper1 Radiologic Diagnostic Criteria for Idiopathic Pulmonary Fibrosis (IPF)

Comparison of the 2011 American Thoracic Society and European Respiratory Society (ATS/ERS) Guidelines2 and the 2018 Fleischner Society White Paper1 Radiologic Diagnostic Criteria for Idiopathic Pulmonary Fibrosis (IPF)
Comparison of the 2011 American Thoracic Society and European Respiratory Society (ATS/ERS) Guidelines2 and the 2018 Fleischner Society White Paper1 Radiologic Diagnostic Criteria for Idiopathic Pulmonary Fibrosis (IPF)

The previously described possible UIP2  pattern has been subdivided into the probable UIP pattern and an indeterminate for UIP pattern1  (Table). The probable UIP pattern is similar to that of a UIP pattern, except honeycombing is absent.1  Interstitial abnormalities in a probable UIP pattern are primarily reticular opacities, with peripheral traction bronchiectasis or bronchiolectasis with a predominantly basal and subpleural, and often heterogeneous, distribution.1  Honeycombing and features to suggest an alternative diagnosis are notably absent.1  The white paper states that “A confident diagnosis of IFP (idiopathic pulmonary fibrosis) can be made in the correct clinical context [emphasis added] when CT imaging shows a pattern of typical or probable UIP (usual interstitial pneumonia),”1(p138) and that “The role of CT is expanded to permit diagnosis of IPF without surgical lung biopsy in select cases [emphasis added] when CT shows a probable UIP pattern.”1(p138) One must be careful not to misinterpret this recommendation to state that histopathologic confirmation is not needed in any patient with a probable UIP pattern on HRCT. Although a probable UIP pattern is highly predictive of a UIP pattern on histopathology, exceptions exist. Raghu et al6  found that a probable UIP pattern on HRCT was highly predictive (94%) of finding a UIP pattern on histopathology. The patient population for that study consisted of patients who were screened for the ARTEMIS-IPF trial (a randomized, placebo-controlled study to evaluate safety and effectiveness of ambrisentan in IPF) and was, therefore, enriched for patients with IPF.6  It is likely that the positive predictive value for a probable UIP pattern in this study would be less if patients in this study consisted of consecutive patients with varied ILDs demonstrating a probable UIP pattern instead of the IPF-enriched patient population for the ARTEMIS-IPF trial. This very high positive predictive value was not reproduced in other studies. Chung et al8  in a multicenter study of 201 patients with pulmonary fibrosis found that 82% of patients with a HRCT read of “probable UIP” had UIP on histopathology. That high, but less than perfect, correlation has important clinical implications. In patients who already have a high pretest probability of IPF (eg, an older male smoker without any risk factors for ILDs) when the HRCT is read as a probable UIP pattern with a high degree of confidence, histopathologic confirmation is not needed. The decision to biopsy should be made on a case-by-case basis in a patient whose pretest probability of IPF is lower, especially if the interpretation of the HRCT pattern is not made with a high confidence. Histopathologic confirmation should be considered in those patients if they do not have risk factors that put them at a high risk for complications and mortality after a surgical lung biopsy. Therefore, in the context of a probable UIP pattern on HRCT, it may be reasonable to make a radiologic diagnosis of IPF in patients with a high pretest probability of IPF and in older patients (who have a higher pretest probability of IPF) with comorbidities, but consideration for biopsy should be given to appropriately selected, younger patients with little functional and physiologic restriction and fewer or no comorbidities; patients who are expected to have low morbidity and no mortality after a surgical lung biopsy.

The remainder of the previously described possible UIP is classified as an indeterminate UIP pattern, which is described as demonstrating fibrosis with some inconspicuous features suggestive of non-UIP pattern and in a variable or diffuse distribution.1  Up to approximately one-half of patients with an indeterminate pattern were found to have findings other than UIP on histopathology.8  Biopsy should be pursued in patients with an indeterminate UIP pattern unless there are contraindications for the surgical procedure in light of the prognostic and therapeutic implications.1 

Another important change in the radiologic nomenclature of ILDs was the renaming of the previously described not UIP pattern2  to CT features most consistent with non-IPF diagnosis.1  That nomenclature change was based on the recognition that, although HRCT findings suggestive of alternative diagnoses make the likelihood of finding a UIP pattern on histopathology significantly less likely, UIP can still be found on histopathology in many patients with those findings on HRCT. Chung et al,8  in a multicenter study of 201 patients with pulmonary fibrosis, found that 50% of patients with CT read as “inconsistent with UIP” had probable or definite UIP on histopathology. Yagihashi et al9  when looking at HRCT-histopathology correlation in patients with a diagnosis of IPF who were enrolled in 3 IPFnet (IPF Clinical Research Network) studies found that 31% of all patients who had histologically definite or probable UIP on histopathology had HRCT features that were “inconsistent” with a diagnosis of UIP. Other studies show that up to 60% of patients demonstrating typical UIP histopathology had CT imaging findings that were not typical for UIP.1,10,11  Areas of decreased attenuation or mosaic attenuation, both suggesting an alternative diagnosis such as hypersensitivity pneumonitis, can be relatively common (43% in one study12  and 27% in another9 ) in patients with biopsy-proven UIP.1  In the correct clinical setting, a diagnosis of IPF should not be excluded if the CT pattern is more suggestive of another ILD, such as nonspecific interstitial pneumonia, chronic hypersensitivity pneumonitis, or sarcoidosis.1  The CT pattern for UIP most frequently overlaps with that of fibrotic, nonspecific interstitial pneumonia.1  Although a confident UIP read on a HRCT is very specific and highly predictive of a UIP pattern on histopathology,37 , it is not very sensitive.1  Only about one-half of patients in an IPF study of 1061 patients were found to have a typical UIP pattern on CT.13  Presence of emphysema also complicates making the diagnosis of IPF on radiology alone. Moreover, HRCT accurately predicted UIP on histopathology in only 50% of 40 patients with emphysema and ILD.14  Histopathologic confirmation is, therefore, recommended when the CT demonstrates HRCT findings suggestive of a non-IPF diagnosis, to confirm the non-IPF diagnosis or to exclude IPF in patients with idiopathic ILDs. Importantly, although the final diagnosis should be based on a consensus opinion after a multidisciplinary discussion, if a typical UIP pattern is noted on histopathology, the pathologist should not be swayed by the HRCT findings (suggestive of non-IPF diagnosis) in calling out a UIP pattern on histopathology as such.

Other factors to consider when forgoing the need for histopathology based on HRCT pattern alone is that radiologists can, and often do, differ on their interpretation and classification of the radiologic findings on HRCT in patients with ILDs.1  A large study showed that interobserver agreement on HRCT reads of various patients with ILD was only moderate for both general radiologists and thoracic radiologists with more than 20 years of experience for both UIP diagnostic categories (mean [SD] = 0.45 [0.13] and 0.48 [0.14], respectively), and for binary diagnosis score (Typical UIP, 0.41; or Possible UIP/Inconsistent with UIP, 0.40).15 

When treating patients with ILDs, determining an accurate diagnosis has important prognostic implications because survival in patients with IPF is significantly worse than it is for patients with other ILDs.16,17  Importantly, getting the diagnosis correct is essential because of the current dichotomy of therapeutic choices available for treating IPF and other ILDs. Corticosteroids and immunosuppressive medications, which are used to treat many non-IPF ILDs, are associated with worse outcomes in patients with IPF when compared with no treatment at all,18  and medications that slow the rate of progression of IPF19,20  have not yet been shown to be effective in, and are not approved for, the treatment of non-IPF ILDs. Inappropriate therapy may, therefore, be worse than no treatment at all.

Additionally, it is important to recognize that although the morbidity and complication rates can appear unreasonably high in unselected patient populations with significant comorbid conditions undergoing a surgical lung biopsy, morbidity and mortality in patients undergoing surgical lung biopsy is primarily driven by the underlying comorbidities, physiologic limitations, and functional limitations, rather than the procedure itself.21,22  Patients with fewer or no comorbidities and relatively few physiologic and functional limitations experience relatively fewer complications and no mortality after a surgical lung biopsy.2332  A surgical lung biopsy should, therefore, be considered in patients with ILDs when a diagnosis cannot be confidently made based on HRCT findings in the appropriate clinical context.

In summary, HRCT is highly predictive of a UIP pattern on histopathology when the HRCT shows a typical UIP pattern on a confident read by the radiologist. The previously described possible UIP pattern can be split into a probable UIP pattern and an indeterminate UIP pattern. A probable UIP pattern is also very predictive of a UIP pattern on histopathology, and histopathologic confirmation is not needed for most patients demonstrating that pattern in the appropriate clinical setting. A UIP pattern may be seen in a substantial proportion of patients with an indeterminate UIP pattern on HRCT and in a variable proportion of patients who demonstrate HRCT patterns suggestive of alternative diseases; histopathologic confirmation should be considered in patients demonstrating these patterns whenever feasible.

1
Lynch
DA
,
Sverzellati
N
,
Travis
WD
, et al.
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper
.
Lancet Respir Med
.
2018
;
6
(
2
):
138
153
.
2
Raghu
G
,
Collard
HR
,
Egan
JJ
, et al
ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis—evidence-based guidelines for diagnosis and management
.
Am J Respir Crit Care Med
.
2011
;
183
(
6
):
788
824
.
3
Swensen
SJ
,
Aughenbaugh
GL
,
Myers
JL
.
Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung
.
Radiology
.
1997
;
205
(
1
):
229
234
.
4
Flaherty
KR
,
Thwaite
EL
,
Kazerooni
EA
, et al.
Radiological versus histological diagnosis in UIP and NSIP: survival implications
.
Thorax
.
2003
;
58
(
2
):
143
148
.
5
Tung
KT
,
Wells
AU
,
Rubens
MB
,
Kirk
JM
,
du Bois
RM
,
Hansell
DM
.
Accuracy of the typical computed tomographic appearances of fibrosing alveolitis
.
Thorax
.
1993
;
48
(
4
):
334
338
.
6
Raghu
G
,
Lynch
D
,
Godwin
JD
, et al.
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial
.
Lancet Respir Med
.
2014
;
2
(
4
):
277
284
.
7
Hunninghake
GW
,
Zimmerman
MB
,
Schwartz
DA
, et al.
Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis
.
Am J Respir Crit Care Med
.
2001
;
164
(
2
):
193
196
.
8
Chung
JH
,
Chawla
A
,
Peljto
AL
, et al.
CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis
.
Chest
.
2015
;
147
(
2
):
450
459
.
9
Yagihashi
K
,
Huckleberry
J
,
Colby
TV
, et al.
Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia
.
Eur Respir J
.
2016
;
47
(
4
):
1189
1197
.
10
Sumikawa
H
,
Johkoh
T
,
Colby
TV
, et al.
Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival
.
Am J Respir Crit Care Med
.
2008
;
177
(
4
):
433
439
.
11
Sverzellati
N
,
Wells
AU
,
Tomassetti
S
, et al.
Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses
.
Radiology
.
2010
;
254
(
3
):
957
964
.
12
Silva
CI
,
Müller
NL
,
Lynch
DA
, et al.
Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT
.
Radiology
.
2008
;
246
(
1
):
288
297
.
13
Raghu
G
,
Wells
AU
,
Nicholson
AG
, et al.
Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
.
Am J Respir Crit Care Med
.
2017
;
195
(
1
):
78
85
.
14
Akira
M
,
Inoue
Y
,
Kitaichi
M
,
Yamamoto
S
,
Arai
T
,
Toyokawa
K.
Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings
.
Radiology
.
2009
;
251
(
1
):
271
279
.
15
Walsh
SL
,
Calandriello
L
,
Sverzellati
N
,
Wells
AU
,
Hansell
DM
;
UIP Observer Consort. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT
.
Thorax
.
2016
;
71
(
1
):
45
51
.
16
Park
JH
,
Kim
DS
,
Park
IN
, et al.
Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes
.
Am J Respir Crit Care Med
.
2007
;
175
(
7
):
705
711
.
17
Mooney
JJ
,
Elicker
BM
,
Urbania
TH
, et al.
Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis
.
Chest
.
2013
;
144
(
2
):
586
592
.
18
Idiopathic Pulmonary Fibrosis Clinical Research Network
,
Raghu
G
,
Anstrom
KJ
,
King
TE
Jr
,
Lasky
JA
,
Martinez
FJ
.
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis
.
N Engl J Med
.
2012
;
366
(
21
):
1968
1977
.
19
King
TE
Jr
,
Bradford
WZ
,
Castro-Bernardini
S
, et al
ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2014; 371(12):1172]
.
N Engl J Med
.
2014
;
370
(
22
):
2083
2092
.
20
Richeldi
L
,
du Bois
RM
,
Raghu
G
, et al
INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2015;373(8):782]
.
N Engl J Med. 2014;
370
(
22
):
2071
2082
.
21
Raj
R
,
Brown
KK
.
Mortality related to surgical lung biopsy in patients with interstitial lung disease: the devil is in the denominator [comment]
.
Am J Respir Crit Care Med
.
2016
;
193
(
10
):
1082
1084
.
22
Raj
R
,
Raparia
K
,
Lynch
DA
,
Brown
KK
.
Surgical lung biopsy for interstitial lung diseases
.
Chest
.
2017
;
151
(
5
):
1131
1140
.
23
Hatch
HB
Jr
,
Blalock
JB
.
Surgical biopsy of the lung
.
Surg Clin North Am
.
1966
;
46
(
6
):
1399
1403
.
24
Ravini
M
,
Ferraro
G
,
Barbieri
B
,
Colombo
P
,
Rizzato
G.
Changing strategies of lung biopsies in diffuse lung diseases: the impact of video-assisted thoracoscopy
.
Eur Respir J
.
1998
;
11
(
1
):
99
103
.
25
Krasna
MJ
,
White
CS
,
Aisner
SC
,
Templeton
PA
,
McLaughlin
JS
.
The role of thoracoscopy in the diagnosis of interstitial lung disease
.
Ann Thorac Surg
.
1995
;
59
(
2
):
348
351
.
26
Petrakis
I
,
Katsamouris
A
,
Drossitis
I
,
Chalkiadakis
G.
Video-assisted thoracoscopic surgery in the diagnosis and treatment of chest diseases
.
Surg Laparosc Endosc Percutan Tech
.
1999
;
9
(
6
):
409
413
.
27
Vansteenkiste
J
,
Verbeken
E
,
Thomeer
M
,
Van Haecke
P
,
Eeckhout
AV
,
Demedts
M.
Medical thoracoscopic lung biopsy in interstitial lung disease: a prospective study of biopsy quality
.
Eur Respir J
.
1999
;
14
(
3
):
585
590
.
28
Blewett
CJ
,
Bennett
WF
,
Miller
JD
,
Urschel
JD
.
Open lung biopsy as an outpatient procedure
.
Ann Thorac Surg
.
2001
;
71
(
4
):
1113
1115
.
29
Yamaguchi
M
,
Yoshino
I
,
Suemitsu
R
, et al.
Elective video-assisted thoracoscopic lung biopsy for interstitial lung disease
.
Asian Cardiovasc Thorac Ann
.
2004
;
12
(
1
):
65
68
.
30
Ishie
RT
,
Cardoso
JJ
,
Silveira
RJ
,
Stocco
L.
Video-assisted thoracoscopy for the diagnosis of diffuse parenchymal lung disease [in English, Portuguese]
.
J Bras Pneumol
.
2009
;
35
(
3
):
234
241
.
31
Fibla
JJ
,
Molins
L
,
Blanco
A
, et al.
Video-assisted thoracoscopic lung biopsy in the diagnosis of interstitial lung disease: a prospective, multi-center study in 224 patients [in English, Spanish]
.
Arch Bronconeumol
.
2012
;
48
(
3
):
81
85
.
32
Luo
Q
,
Han
Q
,
Chen
X
,
Xie
J
,
Wu
L
,
Chen
R.
The diagnosis efficacy and safety of video-assisted thoracoscopy surgery (VATS) in undefined interstitial lung diseases: a retrospective study
.
J Thorac Dis
.
2013
;
5
(
3
):
283
288
.

Author notes

The authors have no relevant financial interest in the products or companies described in this article.